0001665988-26-000027
SEC filingBioventus delivered a strong profitability turnaround in Q1 FY2026, with operating income up 72.8% to $8.4M and net income swinging to $3.1M profit from a $2.6M loss, driven by 6.6% revenue growth to $132.1M, gross margin expansion to 68.7%, and positive cash generation.
Operating income more than doubled, up 72.8% to $8.4 million from $4.9 million, yielding a 6.4% operating margin. This leverage arose as revenue growth outpaced SG&A increases, allowing fixed costs to dilute over a stronger base and amplifying the benefits of gross margin gains into bottom-line expansion.
The profitability inflection extended to the net line, where income reached $3.1 million, or $0.04 diluted EPS, reversing a $2.6 million loss and -$0.04 EPS in Q1 FY2025. Reduced interest expense following debt refinancing and prepayments played a key role, converting operational strength into shareholder value while lowering the cost of capital.